Drugs / JNJ-26113100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00455429 | Apr 2007 → Mar 2009 | atopic eczema | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-26113100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00455429 ↗ |
| Route | Oral | “capsules orally once daily” NCT00455429 ↗ |